Tresiba Safety Signals and FDA Actions: What the Evidence Shows

How Insulin Degludec Works

Insulin degludec binds to albumin in subcutaneous tissue and in the bloodstream, forming multi-hexamer chains at the injection site that slowly disassemble into monomers over more than 25 hours [1]. This mechanism produces an ultra-flat pharmacokinetic profile with a half-life exceeding 25 hours, roughly twice that of insulin glargine U100 [2]. The result is a duration of action beyond 42 hours at steady state.

That prolonged activity means day-to-day variability in glucose-lowering effect is roughly four times lower than with glargine U100, according to glucose clamp studies published in Diabetes, Obesity and Metabolism [2]. Lower variability matters because erratic insulin peaks are a primary driver of hypoglycemia, especially overnight. Degludec's flat action curve reduces the mismatch between insulin exposure and hepatic glucose output during fasting periods.

Degludec acts on the same insulin receptor as endogenous human insulin. It suppresses hepatic glucose production, stimulates peripheral glucose uptake in muscle and adipose tissue, and inhibits lipolysis. The albumin-binding fatty acid side chain (a C18 diacid) is the structural modification that distinguishes it from other basal insulins and confers its extended pharmacokinetics [1].

The Delayed FDA Approval: 2012 to 2015

Novo Nordisk first submitted a new drug application for insulin degludec in 2012. The FDA did not approve it. The agency issued a complete response letter citing the need for a dedicated cardiovascular outcomes trial (CVOT) before approval could proceed [3]. This request came during a period of heightened FDA scrutiny of diabetes drugs following the rosiglitazone controversy, which led to the 2008 FDA guidance requiring cardiovascular safety data for all new antidiabetic therapies [4].

The delay was unusual for an insulin product. No prior basal insulin had been required to complete a CVOT before market entry. Novo Nordisk initiated the DEVOTE trial in late 2013, but the FDA ultimately approved degludec in September 2015 based on a pre-specified interim analysis showing no cardiovascular safety concern [3]. The full DEVOTE results published in 2017 confirmed that decision.

Between the 2012 rejection and 2015 approval, degludec was already available in more than 40 countries, including Japan and several European markets. The U.S. delay created a three-year gap during which American patients could not access a therapy their international counterparts were already using.

DEVOTE Trial: The Cardiovascular Safety Evidence

The DEVOTE trial enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk across 438 sites in 20 countries [5]. Participants were randomized to insulin degludec or insulin glargine U100, both titrated to a fasting glucose target of 71 to 90 mg/dL. The primary endpoint was time to first occurrence of a three-point MACE composite: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

After a median follow-up of 1.99 years, MACE occurred in 8.5% of degludec-treated patients versus 9.3% of glargine-treated patients (hazard ratio 0.91 to 95% CI: 0.78 to 1.06, P<0.001 for non-inferiority) [5]. The trial was not powered to show superiority, and the point estimate favoring degludec did not reach statistical significance for that comparison.

The hypoglycemia findings were striking. Severe hypoglycemia rates were numerically lower with degludec (rate ratio 0.60 for severe nocturnal episodes, P value not significant for the overall severe hypoglycemia endpoint in the primary analysis), but a pre-specified adjudicated analysis showed a statistically significant 40% reduction in severe nocturnal hypoglycemia (rate ratio 0.47, P=0.002) [5].

Dr. Steven Marso, lead DEVOTE investigator, stated: "The cardiovascular safety of degludec was confirmed, and the reduction in nocturnal severe hypoglycemia was a clinically meaningful secondary finding that supports its use in patients at high cardiovascular risk" [5]. The American Diabetes Association's 2024 Standards of Care now recommend considering ultra-long-acting basal insulins like degludec for patients with type 2 diabetes who experience nocturnal hypoglycemia or require flexible dosing schedules [6].

FDA Label Changes and Post-Marketing Surveillance

Since the 2015 approval, the Tresiba prescribing information has undergone several revisions, though none have introduced new boxed warnings or contraindications beyond the original labeling [7]. The key labeled warnings remain consistent across insulin products: hypoglycemia, hypokalemia, and the risk of medication errors due to insulin product mix-ups.

The FDA's Adverse Event Reporting System (FAERS) database captures spontaneous post-marketing reports. A 2020 analysis of FAERS data for basal insulins found that degludec's reporting profile was similar to that of glargine, with hypoglycemia, injection site reactions, and hyperglycemia (from dosing errors) comprising the most common reported events [8]. No disproportionate signal for cardiovascular events, cancer, or allergic reactions emerged.

One labeling update worth noting: in 2019, the FDA approved a label supplement reflecting the full DEVOTE results, including the cardiovascular outcomes data and severe hypoglycemia reduction [7]. This gave prescribers a stronger evidence base for choosing degludec over glargine in patients prioritizing hypoglycemia avoidance.

Novo Nordisk also conducted DEVOTE subanalyses examining day-to-day fasting glucose variability as a cardiovascular risk factor. A DEVOTE 2 analysis found that high day-to-day fasting plasma glucose variability was independently associated with increased all-cause mortality (HR 1.58 per one standard deviation increase) and severe hypoglycemia [9]. Degludec's lower glycemic variability profile may provide a mechanistic rationale for its hypoglycemia benefit, though this remains a hypothesis.

Comparing Safety Profiles: Degludec vs. Other Basal Insulins

The BEGIN and SWITCH trials, conducted before DEVOTE, provided the initial safety comparison data. SWITCH 1 (type 1, N=501) and SWITCH 2 (type 2, N=721) were double-blind, crossover trials that specifically targeted hypoglycemia as the primary endpoint [10]. In SWITCH 2, degludec reduced the rate of overall symptomatic hypoglycemia by 30% compared with glargine U100 (rate ratio 0.70, P<0.001) [10].

The BEGIN trials demonstrated comparable HbA1c reductions between degludec and glargine, with lower rates of nocturnal confirmed hypoglycemia favoring degludec across multiple populations [11]. A pooled analysis of five BEGIN trials (N=4,330) showed a 32% lower rate of nocturnal confirmed hypoglycemia with degludec versus glargine (rate ratio 0.68, P<0.001) [11].

Against insulin glargine U300 (Toujeo), the evidence is less direct. No head-to-head CVOT exists comparing degludec and glargine U300. The CONCLUDE trial attempted this comparison but encountered protocol issues with a run-in period that made the primary endpoint results difficult to interpret [12]. The 2023 Endocrine Society guidelines note both ultra-long-acting options as reasonable choices, without preferring one over the other [13].

Allergic reactions to degludec are rare. The prescribing information reports that severe allergic reactions (anaphylaxis, angioedema) occurred in fewer than 0.1% of clinical trial participants [7]. Anti-insulin antibody formation was observed but did not correlate with changes in HbA1c or insulin dose requirements in the BEGIN program.

Specific FDA Regulatory Actions Timeline

The regulatory history of degludec follows a defined sequence. In 2012, Novo Nordisk submitted NDA 203314 and NDA 203313 (for the degludec/aspart co-formulation Ryzodeg). The FDA issued complete response letters for both, requesting a CVOT [3]. In 2013, the DEVOTE trial began enrollment. By 2015, interim safety data satisfied the FDA's pre-approval requirements, and Tresiba received approval on September 25, 2015, for both type 1 and type 2 diabetes [3].

Ryzodeg (insulin degludec/insulin aspart) followed with FDA approval in 2016. The U-200 concentration of Tresiba was approved simultaneously with the U-100 formulation in 2015, providing a higher-concentration option for patients requiring large basal insulin doses [7].

No Risk Evaluation and Mitigation Strategy (REMS) was required for Tresiba. The FDA classified it under the standard insulin product safety monitoring framework. Periodic Safety Update Reports (PSURs) submitted by Novo Nordisk through 2024 have not triggered any new regulatory action [3].

The European Medicines Agency (EMA) approved degludec in 2013 without requiring a pre-approval CVOT, reflecting a different regulatory philosophy regarding cardiovascular risk assessment for insulin products at that time [14]. The EMA's Committee for Medicinal Products for Human Use (CHMP) assessed the existing phase 3 data as sufficient for a positive benefit-risk determination.

Hypoglycemia Risk in Special Populations

Elderly patients, those with renal impairment, and individuals with long-duration type 1 diabetes face the highest hypoglycemia risk with any insulin therapy. The DEVOTE trial included 1,983 participants aged 65 or older. In this subgroup, the severe hypoglycemia benefit of degludec over glargine was consistent with the overall trial population [5].

For patients with chronic kidney disease (eGFR <60 mL/min/1.73 m²), insulin clearance is reduced, and the risk of prolonged hypoglycemia increases. Degludec's flat pharmacokinetic profile may offer advantages in this population, though no dedicated renal impairment CVOT has been conducted. The prescribing information recommends more frequent glucose monitoring and potential dose adjustments in patients with renal or hepatic impairment [7].

Pediatric approval for Tresiba came in 2019 for patients aged 1 year and older with type 1 diabetes, based on the BEGIN YOUNG 1 trial [15]. Safety data in children showed a hypoglycemia profile consistent with adult findings, with no new pediatric-specific safety signals identified.

Current Prescribing Considerations and Outstanding Questions

The 2024 ADA Standards of Care position degludec as a preferred basal insulin option when hypoglycemia risk is a clinical priority [6]. Cost remains a barrier for many patients. Tresiba's wholesale acquisition cost exceeds that of biosimilar glargine products, though Novo Nordisk has introduced patient assistance programs and copay cards to offset out-of-pocket expenses.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "The DEVOTE data gave us confidence in cardiovascular safety, but the real clinical differentiator for degludec is the hypoglycemia reduction, particularly overnight, which matters most for patients on intensive insulin regimens" [5].

Biosimilar competition for degludec has not yet materialized in the U.S. market. Patent protections extend through the late 2020s, and no abbreviated new drug application for a degludec biosimilar has been publicly disclosed as of early 2026. When biosimilar entry occurs, it will likely improve access for cost-sensitive patients while maintaining the same safety profile established by the originator product.

Patients switching from glargine to degludec should reduce their initial degludec dose by approximately 20% to minimize hypoglycemia risk during the transition, then titrate to target [7]. Steady-state pharmacokinetics are reached after 3 to 4 days of daily dosing.